Correlation Between First Trust and IShares Genomics
Can any of the company-specific risk be diversified away by investing in both First Trust and IShares Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining First Trust and IShares Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between First Trust Nasdaq and iShares Genomics Immunology, you can compare the effects of market volatilities on First Trust and IShares Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in First Trust with a short position of IShares Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of First Trust and IShares Genomics.
Diversification Opportunities for First Trust and IShares Genomics
0.94 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between First and IShares is 0.94. Overlapping area represents the amount of risk that can be diversified away by holding First Trust Nasdaq and iShares Genomics Immunology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on iShares Genomics Imm and First Trust is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on First Trust Nasdaq are associated (or correlated) with IShares Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of iShares Genomics Imm has no effect on the direction of First Trust i.e., First Trust and IShares Genomics go up and down completely randomly.
Pair Corralation between First Trust and IShares Genomics
Given the investment horizon of 90 days First Trust Nasdaq is expected to generate 0.72 times more return on investment than IShares Genomics. However, First Trust Nasdaq is 1.39 times less risky than IShares Genomics. It trades about -0.2 of its potential returns per unit of risk. iShares Genomics Immunology is currently generating about -0.18 per unit of risk. If you would invest 2,796 in First Trust Nasdaq on October 9, 2024 and sell it today you would lose (90.00) from holding First Trust Nasdaq or give up 3.22% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Strong |
Accuracy | 95.0% |
Values | Daily Returns |
First Trust Nasdaq vs. iShares Genomics Immunology
Performance |
Timeline |
First Trust Nasdaq |
iShares Genomics Imm |
First Trust and IShares Genomics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with First Trust and IShares Genomics
The main advantage of trading using opposite First Trust and IShares Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if First Trust position performs unexpectedly, IShares Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IShares Genomics will offset losses from the drop in IShares Genomics' long position.First Trust vs. First Trust Nasdaq | First Trust vs. First Trust Nasdaq | First Trust vs. First Trust Nasdaq | First Trust vs. First Trust Indxx |
IShares Genomics vs. Global X Genomics | IShares Genomics vs. iShares Cybersecurity and | IShares Genomics vs. iShares Self Driving EV |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |